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Abstract: Natural products, sources of new pharmacological substances, have large chemical
diversity and architectural complexity. In this context, some toxins obtained from invertebrate
venoms have anticonvulsant effects. Epilepsy is a neurological disorder that affects about 65 million
people worldwide, and approximately 30% of cases are resistant to pharmacological treatment.
Previous studies from our group show that the denatured venom of the ant Dinoponera quadriceps
(Kempt) protects mice against bicuculline (BIC)-induced seizures and death. The aim of this study
was to investigate the anticonvulsant activity of compounds isolated from D. quadriceps venom
against seizures induced by BIC in mice. Crude venom was fractionated by high-performance
liquid chromatography (HPLC) resulting in six fractions referred to as DqTx1–DqTx6. A liquid
chromatography-mass spectrometry (LC/MS) analysis revealed a major 431 Da compound in fractions
DqTx1 and DqTx2. Fractions DqTx3 and DqTx4 showed a compound of 2451 Da and DqTx5 revealed
a 2436 Da compound. Furthermore, the DqTx6 fraction exhibited a major component with a molecular
weight of 13,196 Da. Each fraction (1 mg/mL) was microinjected into the lateral ventricle of mice,
and the animals were observed in an open field. We did not observe behavioral alterations when
the fractions were given alone. Conversely, when the fractions were microinjected 20 min prior
to the administration of BIC (21.6 nM), DqTx1, DqTx4, and DqTx6 fractions increased the latency
for onset of tonic-clonic seizures. Moreover, all fractions, except DqTx5, increased latency to death.
The more relevant result was obtained with the DqTx6 fraction, which protected 62.5% of the animals
against tonic-clonic seizures. Furthermore, this fraction protected 100% of the animals from seizure
episodes followed by death. Taken together, these findings indicate that compounds from ant venom
might be a potential source of new anticonvulsants molecules.
Keywords: ant venom; neuroactive compounds; bicuculline; tonic-clonic seizures; peptide fraction;
natural product
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1. Introduction
Natural products have a wide chemical diversity and architectural complexity that cannot be
matched by synthetic molecules [1,2]. Animal venoms stand out because of the high specificity and
potency of their toxins in molecular targets of mammalian biological systems [1]. These venoms can
exert noxious effects on several organic systems, such as cardiovascular, nervous, respiratory, and
renal systems, as well as skin and muscles. As a consequence, poisoning victims can experience pain,
swelling, tissue necrosis, vomiting, paralysis, fever, diarrhea, headaches, blurred sight, dizziness,
hypotension, hemorrhage, and even death [3,4]. From another standpoint, some venoms have
beneficial effects [5,6] or can be used as pharmacological tools for probing biochemical pathways and
mechanisms [7,8]. Despite the remarkable potential of venoms, their evaluation and characterization
remains underexplored.
Invertebrates have incorporated a vast range of neurotoxins in their venoms throughout evolution,
and some compounds show high affinity to receptors, ionic channels, and transporters in the central
nervous system (CNS) [7–10]. Previous studies have demonstrated the anticonvulsant effects of toxins
isolated from invertebrate venoms. The peptide fraction (350 µg/animal) isolated from the venom of
the wasp Polybia paulista protected 60% of the rats against generalized tonic-clonic seizures induced
by pentylenotetrazol (PTZ) [11]. Furthermore, parawixin 2 (isolated from the venom of the spider
Parawixia bistriata) protected animals against seizures induced by PTZ, picrotoxin, pilocarpine, and
kainic acid [12], as well as inhibited PTZ-induced kindling of rats [13].
Seizures are the main symptoms of epilepsy, a neurological disorder characterized by an enduring
predisposition to transient abnormal excessive or synchronous neuronal activity. Patients also
present neurobiological, cognitive, psychological, and social consequences of the condition [14,15].
This disorder affects about 65 million people worldwide [16] and approximately 30% of patients are
resistant to pharmacotherapy [17,18]. Furthermore, antiepileptic drugs frequently cause relevant side
effects that range from gastric discomfort to hepatic failure or aplastic anemia [9]. In this context,
invertebrate venoms are a possible source for new anticonvulsant probes [19].
Recently, studies have shown anticonvulsant effects of the crude venom from the giant ant
Dinoponera quadriceps. Lopes et al. [20] demonstrated that intraperitoneal administration of the crude
venom increased the latency for onset of PTZ-induced seizures in mice. Additionally, our group
observed procursive behavior and tonic-clonic seizures after injecting the crude venom into the lateral
ventricle of mice. In contrast, prior administration of the denatured venom protected the animals
against tonic-clonic seizures (66.7%) and death (100%) induced by the gamma aminobutyric acid
GABAA antagonist bicuculline (BIC) [21]. Taken together, these findings demonstrate that D. quadriceps
venom is a potential source of new pro- and anticonvulsants molecules. The aim of the present study
was to investigate the anticonvulsant activity of isolated fractions of D. quadriceps venom on seizures
induced by BIC in mice. We will also verify the effects of the fractions on spontaneous behavior.
2. Results
2.1. HPLC Fractionation and Mass Spectra
The chromatographic profile of the crude venom is shown in Figure 1A. This profile revealed
the presence of the six fractions that were denoted as DqTx1 to DqTx6. The fractions were lyophilized
and used in the biological assays. Each fraction was analyzed by liquid chromatography/eletrospray
ionization-mass spectrometry (LC/ESI-MS). The fractions were monitored at 210 and 280 nm.
The chromatogram revealed initial elution time of 3 and 7 min to fractions DqTx1 and DqTx2,
respectively. ESI-MS spectra of both fractions displayed a major compound with molecular weight
of 431 Da. DqTx3 and DqTx4 fractions had elution times of 34 to 35 min with a major compound
of 2421 Da. Retention time of fraction DqTx5 ranged from 36–38 min with a major compound of 2436 Da
(Figure 1). Furthermore, DqTx6 presented an elution time range from 46–48 min, and the deconvolution
mass spectrum revealed a major compound with molecular weight of 13,196 Da (Figure 2).
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Figure 1. Dinoponera quadriceps crude venom chromatography. (A) Chromatographic profile (reverse‐
phase high performance liquid chromatography—Hitachi system, Phenomenex C18 column (2.6 × 25 
cm, 12 μm, 300 Å) of crude Dinoponera quadriceps venom, showing six major fractions monitored at 
210  (gray)  and  280  (black)  nm  and  eluted  using  a  linear  gradient  from  acetonitrile  containing 
trifluoroacetic acid at 0.1% (TFA) (100% ACN/H2O v/v) for 100 min; (B) ESI mass spectrum (LC/ESI‐
MS—Waters  system, mass  range  between  200  and  2000 m/z,  nitrogen  gas  flow  rate  of  4.1  L∙h−1, 
capillary voltage of 2.3 kV, cone voltage of 32 V, extractor voltage of 8 V, source heater set at 100 °C, 
solvent heater set at 400 °C, ion voltage of 1.0 V, and a multiplier voltage of 800 V) of the fractions of 
DqTx1 to DqTx6. 
1. Dinoponera quadriceps crude venom chromatography. (A) Ch omatographic profile
(reverse-phase high performance liquid ch omatography—Hitachi system, Phenomenex C18 column
2.6 × 25 cm, 12 µm, 300 Å) of crude Dinoponera quadriceps venom, showing six major fractions
monitored t 210 (gray) and 280 (black) nm and eluted using a li ear gradi nt from acetonitrile
containing trifluoroacetic acid at 0.1% (TF ) (100% ACN/H2O v/v) for 100 min; (B) ESI mass spectrum
(LC/ESI-MS—Waters system, mass range between 200 and 2000 m/z, nitrogen gas flow rate of 4.1 L·h−1,
capillary voltage of 2.3 k , cone voltage of 32 , extractor voltage of 8 , source heater set at 100 ◦ ,
solvent heater set at 400 ◦ , ion voltage of 1.0 , and a ultiplier voltage of 800 ) of the fractions of
qTx1 to qTx6.
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Figure 2. Deconvolution electrospray mass spectrum of fraction DqTx6.
2.2. Primary Behavioral Screening
One-way ANOVA did not reveal effect of i.c.v. treatment with fractions of DqTx1 to DqTx6 for
exploratory activity (p = 0.49), grooming (p = 0.07), or immobility (p = 0.679) (Table 1). These fractions
did not induce motor or behavioral alterations in the animals.
Table 1. Effects of injection into the lateral ventricle of fractions of Dinoponera quadriceps venom on
the total time spent in exploratory activities, grooming, and immobility in mice.
Treatment
Behavioral Cluster (s)
Exploration Grooming Immobility
Control (n = 9) 1395.48 ± 56.38 293.14 ± 55.36 111.36 ± 36.47
DqTx1 (n = 7) 1281.37 ± 110.25 352.47 ± 104.24 166.15 ± 93.05
DqTx2 (n = 7) 1250.36 ± 128.08 267.05 ± 58.79 282.58 ± 119.69
DqTx3 (n = 8) 1367.91 ± 58.9 294.31 ± 37.89 137.77 ± 53.78
DqTx4 (n = 8) 1193.58 ± 49.32 493.80 ± 50.81 112.61 ± 44.11
DqTx5 (n = 8) 1250.40 ± 87.55 406.00 ± 38.47 143.59 ± 62.27
DqTx6 (n = 8) 1378.41 ± 84.41 280.44 ± 43.68 141.14 ± 64.03
Data expressed as the mean ± SEM. p > 0.05 (One-way ANOVA).
2.3. Anticonvulsant Assay
As expected, all animals that received vehicle prior to bicuculline administration showed
tonic-clonic seizures (level 5) followed by death (Table 2).
One-way ANOVA revealed effects in latency to onset of seizures (p = 0.029) and latency to death
(p = 0.004) (Table 2). Dunnett’s post hoc analysis detected that groups pretreated with DqTx1 (p =
0.008), DqTx4 (p = 0.044), and DqTx6 (p = 0.002) showed an increase in the mean latency for the onset of
seizures, and for the effect of DqTx3 was marginally significant (p = 0.057) (Table 2). While the control
group presented mean latency of 16.5 ± 6.8 s, DqTx1, DqTx3, DqTx4, and DqTx6 had mean latencies of
1191.14 ± 306.27, 879.28 ± 310.05, 922.86 ± 318.62 and 1225.28 ± 273.44 s, respectively. Similar results
occurred regarding the latency for death; groups that received pretreatment with DqTx1 (p = 0.005),
DqTx2 (p = 0.009), DqTx3 (p = 0.01), DqTx4 (p = 0.025), and DqTx6 (p < 0.001) showed increased latency
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for death (Table 2). While the control group had a mean latency of 509.25 ± 253.24, DqTx1, DqTx2,
DqTx3, DqTx4, and DqTx6 had mean latencies of 1528.71 ± 180.29, 1471.86 ± 169.40, 1453.71 ± 198.99,
1342.71 ± 257.40, and 1800, respectively.
Table 2. Effects of injection into the lateral ventricle of Dinoponera quadriceps venom fractions against
seizures elicited by the bicuculline model in mice.
Parameters
Treatment
Control DqTx1 DqTx2 DqTx3 DqTx4 DqTx5 DqTx6
Median
seizure score 5 5 5 5 5 5 4
Incidence of
seizures
Stage 1 0/8 6/7 4/7 3/7 5/7 3/7 5/8
Stage 2 0/8 4/7 4/7 3/7 5/7 3/7 5/8
Stage 3 0/8 2/7 5/7 2/7 3/7 2/7 4/8
Stage 4 0/8 1/7 2/7 2/7 0/7 1/7 1/8
Stage 5 8/8 4/7 7/7 5/7 4/7 4/7 3/8
Percentage of
protection 0 42.8 0 28.6 42.8 42.8 62.5
#
Percentage of
survival 0 71.4 42.8 71.4 57.1 57.1 100
#
Latency for
the onset of
seizures (s)
16 ± 6 1191 ± 306 * 710 ± 216 879 ± 310 + 923 ± 318 * 812 ± 350 1225 ±273 *
Latency for
death (s) 509 ± 253 1528 ± 180 * 1471 ± 169 * 1453 ± 199 * 1342 ± 257 * 1087 ± 337 1800 *
Incidence of
death 8/8 2/7 4/7 2/7 3/7 3/7 0/8
Bicuculline was injected into the lateral ventricle at a dose of 10 mg/mL following pre-treatment with vehicle or
fractions. # p < 0.05 compared to control (chi-square, followed by residual analysis); * p < 0.05; and + p = 0.057
compared to control (one-way ANOVA followed by Dunnett’s post hoc test).
The analysis of seizures score showed that pretreatment with DqTx1, DqTx4, and DqTx5 fractions
prevented the development of tonic-clonic seizures (level 5) in 42.6% of animals. DqTx3 and DqTx6
fractions protected 28.6% and 62.5% of animals, respectively. Regarding survival, the pretreatment
with DqTx2 prevented the death of 42.8% of animals, DqTx4 and DqTx5 prevented the death of 57.1%
of animals. DqTx1 and DqTx3 protected 71.4% and DqTx6 protected 100% of the animals (Table 2).
3. Discussion
RP-HPLC was a suitable technique to fractionate the Dinoponera quadriceps crude venom
(Figure 1A). The separated fractions are most likely composed of peptides and a small protein.
The ESI-MS spectra revealed that the DqTx1/DqTx2 fractions contained hydrophilic compounds
of low molecular weight. The DqTx 3 and DqTx4 fractions presented the same composition as the
hydrophobic 2451 Da molecular weight compound. Interestingly, the DqTx5 fractions revealed a
hydrophobic compound with a slightly higher molecular weight of 2436 Da. Furthermore, the DqTx6
fraction contained a major hydrophobic compound with a molecular weight of 13,196 Da. This fraction
showed more potent anticonvulsant activity when compared with the other fractions (Table 2), and
will be fractionated further in the future.
Peptides are the most common compounds found in animal venoms, and represent a main source
of bioactive toxins with high affinity and selectivity for a range of targets [9,22]. Venoms from the
ant subfamilies Ponerinae and Myrmeciinae are particularly rich in peptides with antimicrobial
properties, such as ponericins [23], pilosulins [24], and some dinoponeratoxins [25]. Moreover,
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there are other peptides from ant venoms of these subfamilies, such as poneratoxins and poneritoxins,
respectively. Poneratoxins are V-shaped peptides with two α-helices connected by a β-turn, which
modulate voltage-gated sodium channels and block synaptic transmission in the insect CNS [22,26–29].
Poneritoxins are monomeric peptides with one or two disulfide bonds, which inhibit human L-type
voltage-gated calcium channels and have insecticidal activity [30].
Several peptides that were isolated from invertebrate venoms have anticonvulsant properties.
BmK IT2 and BmK AS are β-type toxins isolated from the scorpion Buthus martensis venom, which
increase the latency for onset of seizures and reduce mortality induced by the administration of PTZ
when injected into the rat hippocampus [31,32]. Similarly, CGX-1007 isolated from the cone snail
Conus geographus venom blocks maximal electroshock, audiogenic, threshold tonic extension, PTZ,
picrotoxin, and BIC-induced seizures when injected into the lateral ventricle of mice [33], and reduces
the amygdala-kindled seizure score in rats [34]. Moreover, theω-agatoxin IVA is a voltage-sensitive
calcium channel blocker isolated from the spider Agelenopsis aperta venom that blocks audiogenic
seizures when injected into the lateral ventricle of mice [35]. A peptide fraction isolated from the
Polybia paulista wasp venom increases latency for the onset of seizures and protects 60% of the animals
from tonic-clonic seizures induced by PTZ in rats [11].
Bicuculline (BIC) is a competitive GABAA receptor antagonist that is well established as a model
for the study of seizures in rodents and scanning potential anticonvulsant drugs [36–39]. Despite of
the extreme effectiveness of the BIC (all animals show severe tonic-clonic seizures followed by death),
it is suitable for screening of potentially anticonvulsant substances from natural products [37–41].
In the present study, all fractions protected animals from BIC-induced seizures, death, or both.
For example, DqTx1, DqTx3, and DqTx6 fractions protected animals from seizures (42.8%, 28.6%,
and 62.5%) and death (71.4%, 71.4%, and 100%), respectively. Notwithstanding, it should be pointed
out that all the fractions demonstrated some degree of anticonvulsive effects. In this respect,
an unidentified factor related to the generation of HPLC fractions could be responsible for the
anticonvulsive effects. However, the fractionation technique applied here has been extensively
used, and no study reported an association between the fractionation process and the anticonvulsive
action [39,42–44] or other pharmacological effects [45–51]. Furthermore, the fact that all of the fractions
have anticonvulsant potential is surprising, but not unlikely. Indeed, venoms can have more than one
effective compound regarding a certain pharmacological action [31,32,52–58]. Additionally, as reported
in the results session, the effects were not homogeneous among the fractions, as it would be expected
if the fractionation processes were responsible for the pharmacological activity.
Antiepileptic drugs act by reducing the neuronal excitability through three main mechanisms:
modulating voltage-dependent ion channels, decreasing the excitatory transmission, or increasing
inhibitory neurotransmission mediated by GABA or glycine [59]. Voltage-dependent ion channels
(Na+, Ca2+ or K+) play a crucial role in the action potential and consequently in neurotransmission.
Hence, some venom toxins with anticonvulsant potential target voltage-dependent channels.
For example, the ω-conotoxins MVIIA and GVIA are N-type calcium channels antagonists [60],
whereas the α-type neurotoxins BmK AS and BmK IT2 are sodium channel modulators [31,32].
L-glutamate receptors and transporters are logical targets for anticonvulsant drugs, as they
mediate the majority of excitatory synapses in the human brain. Parawixin 10, a toxin extracted
from P. bistriata, exerts its anticonvulsant activity by increasing glutamate uptake [44]. However,
this mechanism is not common for antiepileptic drugs due to the wide range of side effects [9,59,61].
Several antiepileptic drugs act on the GABAA receptor as direct agonists or increase GABA
availability in the synaptic cleft by blocking uptake [62–64]. The toxins SrTx1 and FrPbA2, isolated
from the venom of the spiders Scaptocosa raptoria and P. bistritata, respectively, act via GABAergic
mechanisms [65].
In the last few years, some studies have demonstrated the pharmacological properties of
D. quadriceps venom. Sousa et al. [66] injected different concentrations of crude venom endovenously
(e.v). 30 min before nociceptive tests (formalin, writhing and hot plate tests). The venom showed
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antinociceptive effects by inhibiting the second phase of the nociceptive response caused by formalin
injection, reducing writhing induced by acetic acid and increasing latency of the response to thermal
stimuli. Cologna et al. [25] evaluated the antimicrobial activity of four peptides from the venom, and
two of them showed activity against Gram-positive and -negative bacteria. Corroborating those data,
Lima et al. [67] reported the antimicrobial activity of the crude venom against methicillin-sensitive and
resistant Staphylococcus aureus strains. The same researchers also reported the antiparasitic effects of
the venom against Leishmania amazonensis and Trypanosoma cruzi [68].
Recently, other studies [69,70] tested the inflammatory activity of the venom using the paw edema
and peritonitis models, showing a dose-dependent inflammatory response in the paw edema model
and an increase in the number of leucocytes and interleukin-1β in the peritoneal fluid. In addition,
the venom also showed anticoagulant and antiplatelet effects in vivo [69].
Regarding the anticonvulsant property, Lopes et al. [20] tested the crude venom through
intraperitoneal (i.p.) and endovenous e.v. routes against three different chemoconvulsants (PTZ,
pilocarpine, and strychnine). As a result, mice that received the venom e.v. before PTZ administration
presented a reduced latency to the first seizure. Conversely, mice that received the venom i.p.
previously to PTZ had an increase in this latency. No effects of the venom were observed in animals that
received pilocarpine or strychnine. These results indicated that D. quadriceps venom has compounds
with convulsant and anticonvulsant properties, which was corroborated in a previous study from our
group [21]. The fractions used herein showed a higher increase in latency to the onset of seizures, and
also promoted increases in the latency to death, in survival, and protection against tonic-clonic seizures
compared to those of Lopes et al. [20]. This difference is probably due to the administration route.
We injected directly into the brain, whereas the venom was systemically administered (e.v. or i.p.)
in the other study. Furthermore, as reported by Cologna et al. [25], there were different peptide
compositions of D. quadriceps venom samples collected from four different regions in Bahia state, with
more similarity observed between samples from the closest areas. Thus, our results may be different
from these of Lopes et al. due to changes in the composition of venom influenced by the environment.
In summary, in the present work the DqTx fractions protected animals from seizures and
death elicited by a GABAA antagonist, and Lopes et al. [20] showed protection against another
GABAA antagonist, but not against drugs acting through other pathways. Thus, we suggest
that the anticonvulsant activity of the DqTx fractions involves GABAergic transmission. Indeed,
recent transcriptome [71] and peptidomic [25] analyses of the D. quadriceps venom revealed the
presence of peptides with similar structures to toxins that interact with ion channels. In addition,
mass spectrometry results showed that the fractions contained low molecular weight substances,
i.e., < 2550 Da (DqTx1-DqTx5) and 13,169 Da (DqTx6). However, the mechanism underlying
the anticonvulsant effects of the DqTx fractions requires further investigation.
In conclusion, D. quadriceps venom is an important source of novel compounds. Our results
indicate that the low molecular weight fractions from ant venom are promising anticonvulsants for
experimental pharmacology. Taken together, these findings will help determine the biological effects of
ant venom components on the mammalian CNS. Further studies are needed to determine the molecular
structures and improve understanding of their effects and therapeutic potential.
4. Material and Methods
4.1. Ant Collection
D. quadriceps specimens were collected in Nísia Floresta (6◦5′ S, 35◦12′ W), Rio Grande do Norte
state, Brazil. Specimens were frozen at −20 ◦C and venom reservoirs were dissected.
4.2. Fractionation and Mass Spectrometry Analysis
Crude content of two hundred venom reservoirs were lyophilized and diluted in 1 mL of
trifluoroacetic acid at 0.1% (TFA/H2O). This solution was submitted to high performance liquid
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chromatography (HPLC; Hitachi, Tokyo, Japan) fractionation using a Phenomenex C18 reverse phase
column (2.6 × 25 cm, 12 µm, 300 Å; Sigma, St. Louis, MO, USA). Elution was carried out with 0.1%
TFA/H2O at a 100% gradient for the first 10 min, followed by a linear gradient from 0% to 100%
acetonitrile (ACN) containing 0.1% TFA for 100 min. Eluates were monitored at 210 and 280 nm and
the main fractions collected were lyophilized and resuspended in 1 mL of distilled water. Six major
fractions were obtained and named DqTx1–DqTx6.
HPLC fractions were analyzed by liquid chromatography electrospray ionization mass
spectrometry (LC/ESI-MS). LC/ESI-MS data were obtained from a Waters instrument (model
3100, Milford, MA, USA) coupled to a Waters Alliance system (model 2695) using a C18 column
(2.0× 150 mm, 3.0 µm particle size, 110 Å pore size, Phenomenex Gemini, Torrance, CA, USA). Solvent
A was 0.1% TFA in water, and solvent B was 60% ACN in solvent A. The gradient was 5%–95% in
solvent B for 30 min, and the peptides were detected at 220 nm. Mass measurements were performed
in a negative mode with the following conditions: mass range between 200–2000 m/z, nitrogen gas
flow rate of 4.1 L·h−1, capillary voltage of 2.3 kV, cone voltage of 32 V, extractor voltage of 8 V, source
heater set at 100 ◦C, solvent heater set at 400 ◦C, ion voltage of 1.0 V, and a multiplier voltage of 800 V.
4.3. Animals
Three-month-old male Swiss mice (30–50 g) were housed with free access to food and water,
with 5–6 animals in plastic cages (20 × 30 × 13 cm), under conditions of controlled temperature
(25 ± 1 ◦C) and a 12 h light/12 h dark cycle (lights on 6:30 a.m.). Animals were handled in accordance
with Brazilian law for the use of animals in research (Law Number 11.794), and all procedures
were approved by the local ethics committee (Federal University of Rio Grande do Norte; protocol
nr. 035/2010, approved 15 September 2010). All efforts were made to minimize animal potential pain,
suffering, or discomfort.
4.4. Surgery
Prior to surgery, mice were anesthetized with intraperitoneal ketamine (100 mg/kg) plus xylazine
(10 mg/kg). Afterwards, the animals were positioned in a stereotaxic frame (Insight, Ribeirão Preto,
Brazil) and skulls were exposed. SA stainless steel guide cannula (25 gauge, 8 mm length) was
implanted in the lateral ventricle, and the stereotaxic coordinates were anterior-posterior = −0.6 mm,
medial-lateral = 1.1 mm, and dorsal-ventral = 1.0 mm from the bregma [72]. The guide cannula was
anchored to the skull with dental acrylic. At the end of the surgery, the cannula was temporarily
sealed with a stainless-steel wire to avoid obstruction. Animals were given one week of post-operative
recovery prior to the start of the experimental proceedings.
4.5. General Procedures
Drug (BIC), vehicle, and chromatography fractions (1 mg/mL) were injected
intracerebroventricular (i.c.v.) at a rate of 0.5 µL/min to a final volume of 1 µL via a microsyringe
pump (Insight, Brazil) with a 10 µL syringe (Hamilton Co., Reno, NV, USA) connected to an injection
needle. After infusion, the needle was left in the guide cannula for an additional 60 s to allow diffusion
from the needle tip. Afterwards, mice were placed in a circular open field (30 cm in diameter with wall
height of 60 cm) located in an experimental room illuminated by a 40 W fluorescent lamp for 30 min.
The behavioral session was recorded by a digital camera placed above the apparatus and behavioral
parameters were registered. The apparatus was cleaned with a 5% alcohol solution after each session.
4.6. Behavioral Analysis
General screening: Animals were randomly assigned to one of the following groups: a control group
that received 1 µL of distilled water (CTR, n = 9); and six experimental groups that received 1 mg/mL
of each fraction (DqTx1, n = 7; DqTx2, n = 7; DqTx3, n = 8; DqTx4, n = 8; DqTx5, n = 8; DqTx6, n = 8).
We quantified the time spent in the following behavioral clusters: exploration (exploration activities
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such as exploratory sniffing, walking, scanning, and erect posture); grooming (grooming of head, snout,
claws, and back); and immobility (complete absence of movements, except for respiratory movements).
Anticonvulsant Assay: The GABAA receptor antagonist bicuculline methbromide (BIC, 10 mg/mL
i.e., 21.6 nM, Sigma, USA) was standardized to provoke tonic-clonic seizures in 100% of the animals in
less than 30 min. Animals were randomly assigned to one of the following groups: a control group
(CTR, n = 8) that was microinjected with vehicle 20 min prior to bicuculline administration; and six
experimental groups that received the fractions DqTx1 to DqTx6 twenty min prior to bicuculline
administration (DqTx1, n = 7; DqTx2, n = 7; DqTx3, n = 7; DqTx4, n = 7; DqTx5, n = 7; DqTx 6, n = 8).
Immediately after the administration of BIC animals were placed in the open field and behavior was
registered for 30 min.
The severity of seizures was evaluated using an adapted Racine’s scale [73], as follows:
(1) myoclonic jerks of contralateral paw; (2) mild paw clonus lasting at least 5 s; (3) severe paw
clonus lasting at least 15 s; (4) rearing in addition to severe paw clonus; and (5) rearing and falling in
addition to severe paw clonus. Moreover, latency to the onset of tonic-clonic seizures (score 5) and
death, survival, and percentage of protection against tonic-clonic seizures were evaluated.
4.7. Verification of the Injection Site
Upon completion of the behavioral procedures, mice were euthanized with intraperitoneal
injection of sodium thiopental (70 mg/kg) and microinjected into the left lateral ventricle with 1.0 µL
of methylene blue stain to mark the site of injection. Brains were removed and manually cut to check
the position of the cannula. Only animals with correct injection sites were included in the analysis.
The same procedure was held if the death occurred before the end of the experiments.
4.8. Statistical Analysis
Data normality and homogeneity of variances were tested by Shapiro-Wilk and Levene tests,
respectively. Comparisons of the behavioral clusters among groups treated with the different fractions
of the venom were held by one-way analysis of variance (ANOVA) followed by Dunnett’s post
hoc (one-tailed). The same tests were used to compare latencies for the onset of seizure and death.
The number of protected animals in the anticonvulsant assays was analyzed using χ2 test, followed
by residual analysis. Differences between medians of score in these assays were analyzed using
the Mann-Whitney test with Bonferroni correction. We considered p < 0.05 as significant values.
All statistical analyses were conducted with PASW Statistics 22 software (IBM, Armonk, NY, USA).
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